Forte Biosciences Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Forte Biosciences Inc
Access all reports
Forte Biosciences Inc. is a clinical-stage biopharmaceutical company in the United States. The company focuses on the development of first-in-class oral drugs for cancer, inflammation and fibrosis. Its lead product candidate is a dual inhibitor of chitin synthesis and metalloproteinases (NanoFol14) for the treatment of solid tumors including lung cancer, pancreatic cancer, glioblastoma and other cancers. The company is also developing ubenimex (a CCR5 antagonist), which is used for HIV entry inhibition; and an anti-angiogenesis drug for treating pancreatic cancer and other indications.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
FBRX
Country
🇺🇸 United States